PMID- 32733897
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 8
DP  - 2020
TI  - Pre-treatment With Ranibizumab Aggravates PDT Injury and Alleviates Inflammatory 
      Response in Choroid-Retinal Endothelial Cells.
PG  - 608
LID - 10.3389/fcell.2020.00608 [doi]
LID - 608
AB  - Polypoidal choroidal vasculopathy (PCV) is the predominant subtype of exudative 
      age-related macular degeneration in Asians. Although photodynamic therapy (PDT) 
      is widely used for PCV treatment, its long-term beneficial effects are 
      unsatisfactory. Accumulating clinical investigations suggest that combined 
      therapy with anti-vascular endothelial growth factor (anti-VEGF) and PDT is 
      superior to PDT monotherapy. However, the optimal time of anti-VEGF before or 
      after PDT remains controversial, hence it needs to further explore the mechanism 
      underlying combined therapy. PDT causes selective damage to endothelial cells, 
      which determines its angio-occlusive efficiency, yet the impact of anti-VEGF on 
      PDT-induced endothelial injury is unclear. Here, we found that pre- compared to 
      post-treatment with anti-VEGF ranibizumab (rani) significantly aggravates PDT 
      injury in the rhesus macaque choroid-retinal endothelial (RF/6A) cell line. PDT 
      activates apoptosis, necroptosis and NLRP3 inflammasome in RF/6A cells. 
      Pre-treatment with rani promotes PDT-caused apoptosis via triggering caspase 
      8-mediated extrinsic apoptosis, and caspase 8 might also play a pivotal role in 
      the rani's function of suppressing PDT-induced necroptosis and NLRP3 inflammasome 
      activation. Our results implicate that pre-treatment with rani may enhance the 
      angio-occlusive efficiency of PDT and alleviate endothelial inflammatory 
      response, which gives it a great advantage over post-treatment.
CI  - Copyright (c) 2020 Liu, Zhu, Gong, Wang, Li and Xu.
FAU - Liu, Yang
AU  - Liu Y
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
FAU - Zhu, Min
AU  - Zhu M
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
FAU - Gong, Ruowen
AU  - Gong R
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
FAU - Li, Lei
AU  - Li L
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
FAU - Xu, Gezhi
AU  - Xu G
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, 
      Fudan University, Shanghai, China.
AD  - NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, 
      Chinese Academy of Medical Sciences, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC7363772
OTO - NOTNLM
OT  - NLRP3/IL-1beta inflammatory response
OT  - PDT
OT  - anti-VEGF
OT  - necroptosis
OT  - pre-treatment
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
PMCR- 2020/01/01
CRDT- 2020/08/01 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fcell.2020.00608 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2020 Jul 9;8:608. doi: 10.3389/fcell.2020.00608. eCollection 
      2020.